StockNews.AI
AZN
StockNews.AI
189 days

AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN

1. A class action lawsuit alleges AstraZeneca engaged in securities fraud. 2. Claims include insurance fraud and legal risks in China affecting operations. 3. Detention of AstraZeneca's China President heightens legal exposure concerns. 4. The lawsuit covers events from February 2022 to December 2024. 5. Investors have until February 21, 2025, to participate as lead plaintiffs.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of fraud can significantly erode investor trust. Previous cases show stock prices often decline during litigation.

How important is it?

This class action could have long-lasting effects on AZN's reputation and stock value. Legal issues often deter investors.

Why Short Term?

The immediate legal challenges will likely affect AZN's stock price. Similar cases have led to rapid price adjustments.

Related Companies

NEW YORK, Feb. 11, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=128376&wire=4

AZN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca's business activities in China; and (5) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT'S NEXT?

If you suffered a loss in AstraZeneca during the relevant time frame, you have until February 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

Related News